Greenwich LifeSciences CEO buys 2,900 shares

Q: What insider transaction did GLSI report in this Form 4?

The Form 4 reports that Snehal Patel, an insider of Greenwich LifeSciences, Inc., purchased shares of the company’s common stock in a direct ownership transaction.

Q: How many Greenwich LifeSciences (GLSI) shares did Snehal Patel buy and at what price?

On 01/12/2026, Snehal Patel bought 2,900 shares of Greenwich LifeSciences common stock at a price of $27.54 per share.

Q: What is Snehal Patel’s role at Greenwich LifeSciences (GLSI)?

Snehal Patel is a director, a 10% owner, and also serves as the company’s CEO and CFO.

Q: How many GLSI shares does Snehal Patel own after this transaction?

After the reported purchase, Snehal Patel beneficially owned 5,602,302 shares of Greenwich LifeSciences common stock.

Q: Was the GLSI insider transaction reported as direct or indirect ownership?

The transaction was reported as direct ownership (D), with no nature of indirect beneficial ownership listed.

Q: What does transaction code "P" mean in this GLSI Form 4?

The transaction code "P" indicates a purchase of common stock, typically in an open market transaction.

Greenwich LifeSciences insider activity: Snehal Patel, who serves as CEO, CFO, director and a 10% owner of Greenwich LifeSciences, Inc., reported buying additional company stock.

Filing Impact

(High)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Greenwich LifeSciences insider activity: Snehal Patel, who serves as CEO, CFO, director and a 10% owner of Greenwich LifeSciences, Inc., reported buying additional company stock. On 01/12/2026, he purchased 2,900 shares of common stock in an open market transaction coded as a "P" transaction at a price of $27.54 per share.

Following this purchase, Patel directly beneficially owned 5,602,302 shares of Greenwich LifeSciences common stock. The filing reflects direct ownership, with no indirect ownership reported in this transaction.

Insider Trade Summary

Net Buyer: 2,900 shares

Net Buy 1 txn

Insider Patel Snehal

Role CEO and CFO

Bought 2,900 shs ($80K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,900	$27.54	$80K

Holdings After Transaction: Common Stock — 5,602,302 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GLSI report in this Form 4?

The Form 4 reports that Snehal Patel, an insider of Greenwich LifeSciences, Inc., purchased shares of the company’s common stock in a direct ownership transaction.

How many Greenwich LifeSciences (GLSI) shares did Snehal Patel buy and at what price?

On 01/12/2026, Snehal Patel bought 2,900 shares of Greenwich LifeSciences common stock at a price of $27.54 per share.

What is Snehal Patel’s role at Greenwich LifeSciences (GLSI)?

Snehal Patel is a director, a 10% owner, and also serves as the company’s CEO and CFO.

How many GLSI shares does Snehal Patel own after this transaction?

After the reported purchase, Snehal Patel beneficially owned 5,602,302 shares of Greenwich LifeSciences common stock.

Was the GLSI insider transaction reported as direct or indirect ownership?

The transaction was reported as direct ownership (D), with no nature of indirect beneficial ownership listed.

What does transaction code "P" mean in this GLSI Form 4?

The transaction code "P" indicates a purchase of common stock, typically in an open market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/14/2026 - 06:05 AM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Snehal

(Last)

(First)

(Middle)

C/O GREENWICH LIFESCIENCES, INC.

3992 BLUEBONNET DR., BUILDING 14

(Street)

STAFFORD

77477

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Greenwich LifeSciences, Inc. [ GLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/12/2026		P		2,900	A	$27.54	5,602,302	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Snehal Patel	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR